scispace - formally typeset
G

Giuseppe G. Pietra

Researcher at University of Pennsylvania

Publications -  65
Citations -  8043

Giuseppe G. Pietra is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Pulmonary hypertension & Lung. The author has an hindex of 34, co-authored 65 publications receiving 7723 citations. Previous affiliations of Giuseppe G. Pietra include Vanderbilt University Medical Center & Hospital of the University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

TL;DR: Recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases.
Journal ArticleDOI

Pathologic assessment of vasculopathies in pulmonary hypertension.

TL;DR: A histopathological classification is proposed that includes both the predominant segment of the pulmonary vasculature affected and the possible coexistence of pathological changes in other vascular segments in PAH.
Journal Article

Muscle fiber orientation and connective tissue content in the hypertrophied human heart.

TL;DR: Results indicate a smooth transition of helix angle from epi- to endocardial surface in the normal left ventricular free wall with nearly 55 per cent of the wall occupied by circumferentially oriented fibers near the cardiac equator.
Journal ArticleDOI

Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

TL;DR: Qualitative histologic examination of lung tissue did not provide a basis for predicting how individual patients would respond to vasodilator agents, but quantitative morphologic analysis of the initial open lung biopsy specimens did prove helpful in predicting acute responsiveness to vasodermal agents and the subsequent clinical course of these patients with unexplained (primary) pulmonary hypertension.